Press releases

October 03, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

September 30, 2025

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Read more

September 19, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

September 08, 2025

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Read more

August 29, 2025

Ultragenyx to Participate at Investor Conferences in September

Read more

August 21, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

August 18, 2025

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Read more

August 05, 2025

Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

Read more

July 31, 2025

Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome

Read more

July 30, 2025

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Read more